IMUC must be a serious buyout target by big pharma right now.
Its the only way for them to stay in the game against NWBO, albeit, as runner-up. IMUC won't be able to compete by themselves unless they are purchased by big pharma. It will take a lot to launch and market a close but no cigar, albeit fantastic, second place treatment. The other big pharma in house immunotherapy treatments will get in line behind these 2 -- but the FDA will allow their development at breakneck speed.
I wouldn't sleep on IMUC. Although they do have a lot of leg work left to do, if they can continue to show good results, there will be a place for them. DCVax - L may be able to treat most of the population (pending results), but that doesn't mean it will work for everyone.